Japan Preclinical Cro Market Size & Outlook, 2023-2030

The preclinical cro market in Japan is expected to reach a projected revenue of US$ 317.0 million by 2030. A compound annual growth rate of 8.1% is expected of Japan preclinical cro market from 2024 to 2030.
Revenue, 2023 (US$M)
$183.6
Forecast, 2030 (US$M)
$317.0
CAGR, 2024 - 2030
8.1%
Report Coverage
Japan

Japan preclinical cro market highlights

  • The Japan preclinical cro market generated a revenue of USD 183.6 million in 2023 and is expected to reach USD 317.0 million by 2030.
  • The Japan market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
  • In terms of segment, toxicology testing was the largest revenue generating service in 2023.
  • Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.


Preclinical cro market data book summary

Market revenue in 2023USD 183.6 million
Market revenue in 2030USD 317.0 million
Growth rate8.1% (CAGR from 2023 to 2030)
Largest segmentToxicology testing
Fastest growing segmentBioanalysis and DMPK studies
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology
Key market players worldwideEurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA


Other key industry trends

  • In terms of revenue, Japan accounted for 3.2% of the global preclinical cro market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 654.3 million by 2030.

Toxicology testing was the largest segment with a revenue share of 22.49% in 2023. Horizon Databook has segmented the Japan preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.


The growing pharmaceutical industry in Japan is contributing to the increasing demand for preclinical trial outsourcing. There has been a significant increase in the number of preclinical trials being conducted in the country as the Japanese government is undertaking steps to offer regulatory support and promote preclinical trials in the country. This is expected to stimulate the market for preclinical services as preclinical testing requires to be conducted in proximity to central development centers.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Preclinical CRO Market Companies

Name Profile # Employees HQ Website

Japan preclinical cro market size, by service, 2018-2030 (US$M)

Japan Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)

Japan preclinical cro market size, by service, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more